{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:01:42Z","timestamp":1781154102756,"version":"3.54.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116830","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:11:04Z","timestamp":1779721864000},"page":"116830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium"],"prefix":"10.1016","volume":"242","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5858-5846","authenticated-orcid":false,"given":"Uri","family":"Ilan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-7423","authenticated-orcid":false,"given":"Alba","family":"Rubio-San-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"van Eijkelenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cormac","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-1670","authenticated-orcid":false,"given":"Lucas","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-3758","authenticated-orcid":false,"given":"Fernando","family":"Carceller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Lecinse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Knox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-2741","authenticated-orcid":false,"given":"Nicole","family":"Scobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4361-3643","authenticated-orcid":false,"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-5813","authenticated-orcid":false,"given":"Pamela","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116830_bib1","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/cncr.33399","article-title":"Use of a clinical trial screening tool to enhance patient accrual","volume":"127","author":"St. Germain","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2026.116830_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29551","article-title":"Access to early-phase clinical trials for children with relapsed and refractory neuroblastoma: a multicentre international study","volume":"69","author":"Cortes","year":"2022","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.ejca.2026.116830_bib3","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib4","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jtho.2017.07.020","article-title":"Thoracic oncology clinical trial eligibility criteria and requirements continue to increase in number and complexity","volume":"12","author":"Garcia","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib5","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1038\/s41598-024-53211-z","article-title":"Clinical trials are becoming more complex: a machine learning analysis of data from over 16,000 trials","volume":"14","author":"Markey","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2026.116830_bib6","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2026.116830_bib7","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1056\/NEJMp1615879","article-title":"Reevaluating eligibility criteria - balancing patient protection and participation in oncology trials","volume":"376","author":"Beaver","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116830_bib8","unstructured":"ICH guideline E8 (R1) on general considerations for clinical studies. 2021."},{"key":"10.1016\/j.ejca.2026.116830_bib9","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research HIV working group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib10","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1200\/JCO.2017.74.0761","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research brain metastases working group","volume":"35","author":"Lin","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib11","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1200\/JCO.2017.74.4144","article-title":"Modernizing clinical trial eligibility: recommendations of the american society of clinical oncology-friends of cancer research minimum age working group","volume":"35","author":"Gore","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib12","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group","volume":"35","author":"Lichtman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib13","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2015.62.1854","article-title":"Modernizing eligibility criteria for molecularly driven trials","volume":"33","author":"Kim","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib14","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamaoncol.2022.1664","article-title":"A new approach to simplifying and harmonizing cancer clinical trials\u2014standardizing eligibility criteria","volume":"8","author":"Gerber","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib15","unstructured":"CTEP_Broadened_Eligibility_Criteria_Guidance 2024."},{"key":"10.1016\/j.ejca.2026.116830_bib16","unstructured":"Enhancing Participation in Clinical Trials-Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. 2025."},{"key":"10.1016\/j.ejca.2026.116830_bib17","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.22.00033","article-title":"The critical role of academic clinical trials in pediatric cancer drug approvals: design, conduct, and fit for purpose data for positive regulatory decisions","volume":"40","author":"De Wilde","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib18","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s41375-023-01856-6","article-title":"Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 therapeutic advances in childhood leukemia and lymphoma (TACL) study","volume":"37","author":"Gossai","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2026.116830_bib19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/annonc\/mdy002","article-title":"Joint adolescent\u2013adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform\u2014ACCELERATE","volume":"29","author":"Gaspar","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib20","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-16-0449","article-title":"The effect of hepatic impairment on outcomes in phase I clinical trials in cancer subjects","volume":"22","author":"Mansfield","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116830_bib21","unstructured":"Cancer clinical trial eligibility criteria: patients with organ dysfunction or prior or concurrent malignancies guidance for industry. 2020."},{"key":"10.1016\/j.ejca.2026.116830_bib22","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-11-2217","article-title":"Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience","volume":"18","author":"Wheler","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116830_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115627","article-title":"Prognostic factors of early mortality in children and adolescents with relapsed\/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: an ITCC study","volume":"227","author":"Carceller","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116830_bib24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1634\/theoncologist.2019-0615","article-title":"A systematic review of pediatric phase I trials in oncology: toxicity and outcomes in the era of targeted therapies","volume":"25","author":"Cohen","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2026.116830_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1423484","article-title":"Safety and outcome of children, adolescents and young adults participating in phase I\/II clinical oncology trials: a 9-year center experience","volume":"12","author":"Pujol Manresa","year":"2024","journal-title":"Front Pediatr"},{"key":"10.1016\/j.ejca.2026.116830_bib26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116830_bib27","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1200\/JCO.2010.34.5074","article-title":"Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors","volume":"30","author":"Olmos","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116830_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","article-title":"Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm-Score)","volume":"84","author":"Bigot","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116830_bib29","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-21-0094","article-title":"The pediatric precision oncology INFORM registry: clinical outcome and benefit for patients with very high-evidence targets","author":"van Tilburg","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116830_bib30","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/2159-8290.CD-21-1136","article-title":"The European MAPPYACTS trial: precision medicine program in pediatric and adolescent patients with recurrent malignancies","volume":"12","author":"Berlanga","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116830_bib31","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3390\/cancers14041048","article-title":"Association between prior malignancy exclusion criteria and age disparities in cancer clinical trials","volume":"14","author":"Patel","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116830_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-017-2698-z","article-title":"Outcome of children and adolescents with central nervous system tumors in phase I trials","volume":"137","author":"Carceller","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2026.116830_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116830_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2013-06-509463","article-title":"Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group","volume":"123","author":"Buitenkamp","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116830_bib35","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood.2024025541","article-title":"Fanconi anemia: realizing hematopoietic cure","volume":"144","author":"Satty","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116830_bib36","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41375-018-0265-z","article-title":"Inotuzumab ozogamicin in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"33","author":"Bhojwani","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2026.116830_bib37","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/blood-2021-148967","article-title":"Blinatumomab associated seizure risk in patients with down syndrome and b-lymphoblastic leukemia: an interim report from children\u2019s oncology group (COG) Study AALL1731","volume":"138","author":"Li","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2026.116830_bib38","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2026.116830_bib39","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7150\/jca.4714","article-title":"The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials","volume":"3","author":"Borad","year":"2012","journal-title":"J Cancer"},{"key":"10.1016\/j.ejca.2026.116830_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001813-199901000-00001","article-title":"Patients who are receiving concomitant medications should not systematically be excluded from phase I studies","volume":"10","author":"Genre","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2026.116830_bib41","unstructured":"Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products-Content and Format Guidance for Industry DRAFT GUIDANCE. n.d."},{"key":"10.1016\/j.ejca.2026.116830_bib42","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2468-2667(21)00100-6","article-title":"Improving diversity in research and trial participation: the challenges of language","volume":"6","author":"Willis","year":"2021","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ejca.2026.116830_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","article-title":"Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature","volume":"14","author":"Onakpoya","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2026.116830_bib44","unstructured":"World Medical Association Declaration of Helsinki JAMA. 3337110.1001\/jama.2024.219722025."},{"key":"10.1016\/j.ejca.2026.116830_bib45","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(22)00176-3","article-title":"Disparity in the selection of patients in clinical trials","volume":"399","author":"Habibzadeh","year":"2022","journal-title":"Lancet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926006118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:56:11Z","timestamp":1781153771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926006118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":45,"alternative-id":["S0959804926006118"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116830","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116830"}}